Extended Data Table 2 | Effect of tocilizumab treatment and RIPK1 caspase cleavage site mutations is absent in known
autoinflammatory diseases
a, Inflammatory markers in subjects treated with tocilizumab. The first time point for each subject is from 3 days before the first tocilizumab injection. P3 had two measurements from the same
week at his 10-month post-tocilizumab evaluation. Reference ranges are given in brackets. b, Variant databases in which mutations in the RIPK1 caspase cleavage site are absent. Variant data-
bases are not independent.
c, Result of additional screening for mutations in the RIPK1 caspase cleavage site.
ALPS, autoimmune lymphoproliferative syndrome; NHGRI, National Human Genome Research Institute; NHLBI, National Heart, Lung, and Blood Institute; NIEHS, National Institute of Environ-
mental Health Sciences.